November 13th, 2026ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand EczemaExperts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.Read more
November 19th, 2026ABCs in Dermatology: Evolving Therapies and Dermatology's Role in Cutaneous Lupus CareAckerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.Read more
November 19th, 2026Q&A: Interpreting Pediatric Nemolizumab Data for AD, With Lawrence Eichenfield, MDLawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.Read more
November 13th, 2026Omalizumab, Remibrutinib Show Similar Early CSU Gains in Indirect AnalysisA post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.Read more
November 12th, 2026Q&A: Healthy Skin Month—What Clinicians Should Watch in Skin Cancer CareLeigh Ann Pansch, MSN, FNP-BC, DCNP, discusses year-round photoprotection, missed skin cancer detection, and overlooked patients for Healthy Skin Month.Read more
November 12th, 2026Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU ControlPost hoc analyses at ACAAI 2026 show 41.7% of patients-maintained CSU control and quality of life 16 weeks after stopping omalizumab.Read more
November 11th, 2026Dupilumab May Slow Atopic March in Atopic Dermatitis: Meta-AnalysisDupilumab cut new or worsening allergies by 34% vs placebo in a 12-trial atopic dermatitis meta-analysis, suggesting it may slow the atopic march.Read more
November 10th, 2026Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MDEmma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.Read more